JP2009528437A - 生分解性発泡体 - Google Patents
生分解性発泡体 Download PDFInfo
- Publication number
- JP2009528437A JP2009528437A JP2008557415A JP2008557415A JP2009528437A JP 2009528437 A JP2009528437 A JP 2009528437A JP 2008557415 A JP2008557415 A JP 2008557415A JP 2008557415 A JP2008557415 A JP 2008557415A JP 2009528437 A JP2009528437 A JP 2009528437A
- Authority
- JP
- Japan
- Prior art keywords
- foam
- gel
- chitosan
- optionally
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006260 foam Substances 0.000 title claims abstract description 340
- 150000004676 glycans Chemical class 0.000 claims abstract description 63
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 63
- 239000005017 polysaccharide Substances 0.000 claims abstract description 63
- 239000011148 porous material Substances 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000002156 mixing Methods 0.000 claims abstract description 27
- 239000006185 dispersion Substances 0.000 claims abstract description 23
- 238000001035 drying Methods 0.000 claims abstract description 22
- 239000004088 foaming agent Substances 0.000 claims abstract description 16
- 238000007493 shaping process Methods 0.000 claims abstract description 14
- 239000004014 plasticizer Substances 0.000 claims abstract description 13
- 239000000654 additive Substances 0.000 claims abstract description 9
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 6
- 238000010907 mechanical stirring Methods 0.000 claims abstract description 5
- 238000007605 air drying Methods 0.000 claims abstract description 4
- 229920001661 Chitosan Polymers 0.000 claims description 125
- 150000002500 ions Chemical class 0.000 claims description 73
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 41
- 229940072056 alginate Drugs 0.000 claims description 40
- 235000010443 alginic acid Nutrition 0.000 claims description 40
- 229920000615 alginic acid Polymers 0.000 claims description 40
- 229920001222 biopolymer Polymers 0.000 claims description 38
- 239000000499 gel Substances 0.000 claims description 30
- 239000002131 composite material Substances 0.000 claims description 26
- 239000004604 Blowing Agent Substances 0.000 claims description 24
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 22
- 229940014041 hyaluronate Drugs 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 238000004132 cross linking Methods 0.000 claims description 15
- 238000001879 gelation Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 206010052428 Wound Diseases 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 239000002250 absorbent Substances 0.000 claims description 13
- 230000002745 absorbent Effects 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000003381 deacetylation reaction Methods 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 230000006196 deacetylation Effects 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 238000005187 foaming Methods 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 238000010894 electron beam technology Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229910001427 strontium ion Inorganic materials 0.000 claims 2
- 238000009941 weaving Methods 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 229910001422 barium ion Inorganic materials 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000005251 gamma ray Effects 0.000 claims 1
- 239000002874 hemostatic agent Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000004745 nonwoven fabric Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 238000009987 spinning Methods 0.000 claims 1
- 239000002759 woven fabric Substances 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 abstract description 7
- 239000004621 biodegradable polymer Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 33
- 150000003839 salts Chemical class 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 15
- 229920002674 hyaluronan Polymers 0.000 description 15
- 229960003160 hyaluronic acid Drugs 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 13
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- 229960002920 sorbitol Drugs 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000017423 tissue regeneration Effects 0.000 description 6
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 238000006065 biodegradation reaction Methods 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 230000000181 anti-adherent effect Effects 0.000 description 4
- -1 calcium (2+) cations Chemical class 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000007799 cork Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000012209 glucono delta-lactone Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004581 coalescence Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HXNZTJULPKRNPR-UHFFFAOYSA-N borinine Chemical compound B1=CC=CC=C1 HXNZTJULPKRNPR-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- ODDZENUCCGSDGC-UHFFFAOYSA-N copper;n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;gold(1+);tetracyanide Chemical compound [Cu+2].[Au+].[Au+].N#[C-].N#[C-].N#[C-].N#[C-].NCCNCCNCCNCCN ODDZENUCCGSDGC-UHFFFAOYSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-M D-glucopyranuronate Chemical compound OC1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000000182 glucono-delta-lactone Substances 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- KQCBYLOBOGMDSY-OMCTUWBCSA-N n-[(2r,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide;2-hydroxybutanedioic acid Chemical compound OC(=O)C(O)CC(O)=O.O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 KQCBYLOBOGMDSY-OMCTUWBCSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000008443 scarless fetal wound healing Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Glass Compositions (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77786906P | 2006-03-01 | 2006-03-01 | |
| US87284406P | 2006-12-05 | 2006-12-05 | |
| US87417406P | 2006-12-11 | 2006-12-11 | |
| PCT/US2007/005435 WO2007103208A2 (en) | 2006-03-01 | 2007-03-01 | Biodegradable foam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528437A true JP2009528437A (ja) | 2009-08-06 |
| JP2009528437A5 JP2009528437A5 (https=) | 2010-04-08 |
Family
ID=38328938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557415A Pending JP2009528437A (ja) | 2006-03-01 | 2007-03-01 | 生分解性発泡体 |
| JP2008557416A Ceased JP2009529926A (ja) | 2006-03-01 | 2007-03-01 | ゲル化複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557416A Ceased JP2009529926A (ja) | 2006-03-01 | 2007-03-01 | ゲル化複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070254016A1 (https=) |
| EP (2) | EP1988937A2 (https=) |
| JP (2) | JP2009528437A (https=) |
| AT (1) | ATE517645T1 (https=) |
| AU (2) | AU2007224138B2 (https=) |
| BR (2) | BRPI0708422A2 (https=) |
| CA (2) | CA2643084C (https=) |
| IL (2) | IL193640A (https=) |
| NO (2) | NO20083696L (https=) |
| WO (2) | WO2007103209A2 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503656A (ja) * | 2009-09-01 | 2013-02-04 | メドヴェント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 組織ドレッシングキット |
| JP2013529464A (ja) * | 2010-06-22 | 2013-07-22 | ウニヴェルシテ ド ルアン | ３ｄ細胞培養に用いる改良された架橋ヒアルロナンヒドロゲル |
| JP2014514330A (ja) * | 2011-04-29 | 2014-06-19 | ケーシーアイ ライセンシング インク | 創傷環境における治療因子の結合のためのアプタマー変性高分子材料 |
| JP2015527478A (ja) * | 2012-09-07 | 2015-09-17 | スリーエム イノベイティブ プロパティズ カンパニー | シリコーン組成物及び関連方法 |
| JP2017032498A (ja) * | 2015-08-05 | 2017-02-09 | 株式会社武蔵野化学研究所 | エンドトキシンの測定用試料の前処理方法 |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
| US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
| US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
| US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
| US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
| GB0508531D0 (en) | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
| WO2008073965A2 (en) | 2006-12-12 | 2008-06-19 | C.R. Bard Inc. | Multiple imaging mode tissue marker |
| CN101778891B (zh) * | 2007-06-13 | 2013-01-16 | Fmc有限公司 | 涂覆藻酸盐的含多糖凝胶泡沫复合物,其制备方法及其应用 |
| DE102007037051A1 (de) * | 2007-07-24 | 2009-01-29 | Aesculap Ag | Flächiges Implantat |
| EP2200674A2 (en) * | 2007-09-10 | 2010-06-30 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
| CA2699868A1 (en) | 2007-09-19 | 2009-03-26 | Surmodics, Inc. | Biocompatible foams, systems, and methods |
| DE102007051059B4 (de) * | 2007-10-18 | 2014-04-03 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Bioverbundmaterial für die kontrollierte Freisetzung von Wirkstoffen |
| WO2009060438A2 (en) | 2007-11-05 | 2009-05-14 | Technion - Research & Development Foundation Ltd | Adhering bandage and methods of applying the same |
| HUE043133T2 (hu) | 2007-11-21 | 2019-07-29 | Smith & Nephew | Sebkötözés |
| EP2987510B1 (en) | 2007-11-21 | 2020-10-28 | T.J. Smith & Nephew Limited | Suction device and dressing |
| GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
| US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| US20130096518A1 (en) | 2007-12-06 | 2013-04-18 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
| GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
| US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
| GB0902816D0 (en) | 2009-02-19 | 2009-04-08 | Smith & Nephew | Fluid communication path |
| WO2010117266A1 (en) | 2009-04-06 | 2010-10-14 | Broockeville Corporation N.V. | In situ gelling alginate systems |
| EP2638922B1 (en) | 2009-06-01 | 2017-03-08 | Technion Research & Development Foundation Ltd. | Multi-components adhesives, manufacturing thereof, and applications thereof |
| EP2462167A4 (en) | 2009-08-07 | 2015-07-01 | Fmc Corp | CARRAGE PRODUCTS, AND METHOD FOR THEIR PREPARATION AND USE |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| GB201011173D0 (en) | 2010-07-02 | 2010-08-18 | Smith & Nephew | Provision of wound filler |
| JP6042815B2 (ja) * | 2010-10-08 | 2016-12-14 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜 |
| GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
| EP2643412B1 (en) | 2010-11-25 | 2016-08-17 | Smith & Nephew PLC | Composition i-ii and products and uses thereof |
| WO2012127224A1 (en) * | 2011-03-21 | 2012-09-27 | University Of Reading | Transport of cells in hydrogels |
| RU2471824C1 (ru) * | 2011-07-26 | 2013-01-10 | Учреждение Российской академии наук Институт высокомолекулярных соединений РАН | Биосовместимый биодеградируемый пористый композиционный материал и способ его получения |
| US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
| US20130288932A1 (en) * | 2012-04-27 | 2013-10-31 | Halliburton Energy Services, Inc. | Methods of cryodesiccating a broth comprising a biopolymer of an exopolysaccharide |
| WO2014086996A1 (en) * | 2012-12-07 | 2014-06-12 | Baxter International Inc. | Hemostatic foam |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| EP2931327B1 (en) | 2012-12-11 | 2019-02-13 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| US20140242676A1 (en) * | 2013-02-01 | 2014-08-28 | Los Alamos National Security, Llc | Artificial leaf-like microphotobioreactor and methods for making the same |
| US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
| EP2968647B1 (en) | 2013-03-15 | 2022-06-29 | Smith & Nephew plc | Wound dressing sealant and use thereof |
| JP6367188B2 (ja) * | 2013-05-29 | 2018-08-01 | 株式会社大塚製薬工場 | 癒着防止材 |
| FR3039555B1 (fr) | 2015-07-30 | 2017-08-18 | Univ Toulouse Iii - Paul Sabatier | Procede de preparation de matrices poreuses polymeres biocompatibles et biodegradables trimensionnelles et applications |
| US20170157283A1 (en) | 2015-12-08 | 2017-06-08 | Medtronic Xomed, Inc. | Dissolvable nasal sinus sponge |
| CA3015172A1 (en) | 2016-02-18 | 2017-08-24 | Privo Technologies, Inc. | Two-stage microparticle-based therapeutic delivery system and method |
| EP3485921B1 (en) | 2016-07-13 | 2025-07-23 | Mochida Pharmaceutical Co., Ltd. | Adhesion-preventing composition |
| WO2018117548A1 (ko) | 2016-12-23 | 2018-06-28 | 주식회사 엘지화학 | 다공성 고흡수성 수지의 제조 방법 및 다공성 고흡수성 수지 |
| US20180235899A1 (en) * | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| FR3068039B1 (fr) | 2017-06-22 | 2020-07-10 | Jellynov | Composition auto-moussante en milieu acide et procede de preparation |
| US10980913B2 (en) | 2018-03-05 | 2021-04-20 | Ethicon Llc | Sealant foam compositions for lung applications |
| WO2020087181A1 (en) * | 2018-11-02 | 2020-05-07 | Covalon Technologies Inc. | Foam compositions, foam matrices and methods |
| FR3089224B1 (fr) | 2018-12-04 | 2020-12-11 | Jellynov | Composition auto-moussante en milieu acide et procédé de préparation |
| CN113727672B (zh) * | 2019-02-07 | 2026-01-06 | 拜欧雷兹有限公司 | 用于软组织的修复、重建和再生的复合支架 |
| AU2020222315B2 (en) | 2019-02-15 | 2025-08-21 | Kenvue Brands Llc | Moldable gel cleanser |
| NL2022788B1 (en) * | 2019-03-22 | 2020-09-28 | No Ceuticals B V | Chitosan nitrate for use as a nitric oxide donor (NO donor) |
| AU2020310211A1 (en) * | 2019-07-11 | 2022-02-24 | StenCo, LLC | Biodegradable material |
| CN110960722A (zh) * | 2019-12-14 | 2020-04-07 | 广东泰宝医疗科技股份有限公司 | 一种抗菌藻酸盐创口贴及其制备方法 |
| CN111888524A (zh) * | 2020-08-04 | 2020-11-06 | 宁波迪创医疗科技有限公司 | 一种组织填充材料及其制备方法、组织工程支架和应用 |
| US11771122B2 (en) | 2020-09-29 | 2023-10-03 | Nitto Denko Corporation | Foam body and method for manufacturing the same |
| KR20240041285A (ko) | 2021-06-01 | 2024-03-29 | 프리보 테크놀로지스, 인코포레이티드 | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 |
| US20230104197A1 (en) * | 2021-10-04 | 2023-04-06 | Cruz Foam, Inc. | Biodegradable foam with alginate |
| KR102866271B1 (ko) * | 2021-10-14 | 2025-10-01 | 킴벌리-클라크 월드와이드, 인크. | 미세다공성 초흡수성 물질 |
| CN114403240B (zh) * | 2022-01-07 | 2023-07-21 | 华南农业大学 | 一种新型米糠蛋白基起酥油替代物及其在烘焙食品中的应用 |
| EP4417243A1 (de) * | 2023-02-15 | 2024-08-21 | Heraeus Medical GmbH | Implantat zur verzögerten wirkstofffreisetzung |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05214156A (ja) * | 1991-10-15 | 1993-08-24 | Merck & Co Inc | ゲル化発泡体 |
| JPH06510330A (ja) * | 1992-06-19 | 1994-11-17 | アルバニー インターナショナル コーポレイション | 多糖フォームの製造方法 |
| JPH08337674A (ja) * | 1995-06-07 | 1996-12-24 | Albany Internatl Res Co | 多糖フォームの製造方法 |
| JP2001278984A (ja) * | 2000-01-24 | 2001-10-10 | Kuraray Co Ltd | 水膨潤性高分子ゲルおよびその製造法 |
| JP2002105233A (ja) * | 2000-09-29 | 2002-04-10 | Kuraray Co Ltd | 多糖類スポンジの製造法及び多糖類スポンジ |
| US20040071776A1 (en) * | 2000-11-22 | 2004-04-15 | Vincent Boudy | Porous plymeric biomaterials, preparation method and uses |
| WO2005023323A1 (en) * | 2003-09-08 | 2005-03-17 | Fmc Biopolymer As | Gelled biopolymer based foam |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128551A (en) * | 1934-01-11 | 1938-08-30 | Algin Corp Of America | Method of treating seaweed |
| US2036934A (en) * | 1934-04-21 | 1936-04-07 | Kelco Co | Process for making alginic acid and product |
| US2246125A (en) * | 1941-04-01 | 1941-06-17 | Gen Electric | Electric discharge device |
| US2426125A (en) * | 1944-04-03 | 1947-08-19 | Kelco Co | Manufacture of glycol alginates |
| US3772266A (en) * | 1972-10-19 | 1973-11-13 | Kelco Co | Process for the preparation of propylene glycol alginate from partially neutralized alginic acid |
| CA1019326A (en) * | 1974-07-16 | 1977-10-18 | Uniroyal Ltd. | Process for the production of alkylene glycol alginates |
| US3929678A (en) * | 1974-08-01 | 1975-12-30 | Procter & Gamble | Detergent composition having enhanced particulate soil removal performance |
| GB1570485A (en) | 1975-11-18 | 1980-07-02 | Robinson & Sons Ltd | Absorbent material for aqueous fluids |
| US4292972A (en) * | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
| US5735902A (en) * | 1987-07-20 | 1998-04-07 | Regen Biologics, Inc. | Hand implant device |
| DE3832643A1 (de) * | 1988-09-26 | 1990-03-29 | Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh | Verfahren zur herstellung einer reflexionsbeschichtung bei hochdruckentladungslampen |
| US4948575A (en) * | 1989-01-24 | 1990-08-14 | Minnesota Mining And Manufacturing Company | Alginate hydrogel foam wound dressing |
| US5260345A (en) * | 1991-08-12 | 1993-11-09 | The Procter & Gamble Company | Absorbent foam materials for aqueous body fluids and absorbent articles containing such materials |
| US5851461A (en) * | 1992-06-19 | 1998-12-22 | Albany International Research Co. | Method of producing polysaccharide foams |
| US5840777A (en) * | 1992-06-19 | 1998-11-24 | Albany International Corp. | Method of producing polysaccharide foams |
| US20030224022A1 (en) * | 1993-01-19 | 2003-12-04 | Amos Nussinovitch | Hydrocolloid cellular solid matrices |
| IL104441A (en) * | 1993-01-19 | 2001-01-28 | Yossi Res Dev Company Of The H | Sponges from hydrocolloids and method for their production |
| US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| TW369414B (en) * | 1994-09-30 | 1999-09-11 | Yamanouchi Pharma Co Ltd | Bone formation transplant |
| US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
| US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
| US5709934A (en) * | 1994-11-22 | 1998-01-20 | Tissue Engineering, Inc. | Bipolymer foams having extracellular matrix particulates |
| JP2822174B2 (ja) * | 1996-03-01 | 1998-11-11 | オーミケンシ株式会社 | キチンキトサン繊維及び構造体の製造法 |
| GB9608222D0 (en) * | 1996-04-20 | 1996-06-26 | Innovative Tech Ltd | Dehydrated hydrogels |
| IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| US6054142A (en) * | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
| CA2266581C (en) * | 1996-09-19 | 2007-03-13 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
| GB2318577B (en) * | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
| GB9704749D0 (en) * | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
| ES2205467T3 (es) * | 1997-03-31 | 2004-05-01 | The Regents Of The University Of Michigan | Matrices biodegradables de poros abiertos. |
| EP1023087A2 (en) * | 1997-10-17 | 2000-08-02 | Advanced Medical Solutions Limited | Foam materials |
| IL124957A0 (en) * | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
| KR100298846B1 (ko) | 1998-09-24 | 2003-10-22 | 한국원자력연구소 | 중화키토산스폰지또는중화키토산/콜라겐혼합스폰지를이용한인공진피 |
| US7128929B1 (en) * | 1999-04-29 | 2006-10-31 | Scherr George H | Alginate foam compositions |
| WO2001006973A1 (en) * | 1999-07-28 | 2001-02-01 | United States Surgical Corporation | Hyaluronic acid anti-adhesion barrier |
| US20030095993A1 (en) * | 2000-01-28 | 2003-05-22 | Hanne Bentz | Gel-infused sponges for tissue repair and augmentation |
| AU2001234623A1 (en) * | 2000-01-28 | 2001-08-07 | Orthogene, Inc. | Gel-infused sponges for tissue repair and augmentation |
| IT1320163B1 (it) | 2000-02-15 | 2003-11-18 | Novamont Spa | Foglia e prodotti formati a base di amido espanso. |
| CA2401869A1 (en) * | 2000-03-03 | 2001-09-07 | Syntacoll Ag | Agent for the treatment of wounds |
| US6565960B2 (en) * | 2000-06-01 | 2003-05-20 | Shriners Hospital Of Children | Polymer composite compositions |
| US7041868B2 (en) * | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
| EP1401352B1 (en) * | 2001-06-14 | 2012-03-21 | Kenton W. Gregory | Method for producing a chitosan wound dressing |
| US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
| US20050147656A1 (en) * | 2001-06-14 | 2005-07-07 | Hemcon, Inc. | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
| US6696077B2 (en) * | 2001-07-26 | 2004-02-24 | George H. Scherr | Silver alginate foam compositions |
| US20030180242A1 (en) | 2001-11-01 | 2003-09-25 | The Procter & Gamble Company | Personal care compositions containing a water-disintegratable polymeric foam |
| US20030186826A1 (en) | 2001-11-01 | 2003-10-02 | The Procter & Gamble Company | Method of using personal care compositions containing a high density, water disintegratable, polymeric foam |
| US6960617B2 (en) * | 2002-04-22 | 2005-11-01 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
| US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
| US20040082063A1 (en) * | 2002-10-18 | 2004-04-29 | Reliance Life Sciences Pvt. Ltd. | Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture |
| US7993922B2 (en) * | 2002-10-18 | 2011-08-09 | Reliance Life Sciences Pvt. Ltd. | Three-dimensional tissue equivalent using macromass culture |
| KR100984184B1 (ko) * | 2003-03-18 | 2010-09-28 | 에스케이케미칼주식회사 | 알긴산 스폰지 및 그의 제조방법 |
| NZ547829A (en) * | 2003-12-23 | 2009-04-30 | Fmc Biopolymer As | Use of alginate matrices to control cell growth |
| GB0329773D0 (en) * | 2003-12-23 | 2004-01-28 | Perry Forbes G D | Torque equalisation in toric transmissions |
| US20050148963A1 (en) | 2004-01-05 | 2005-07-07 | Brennan H. G. | Bioabsorbable surgical sponge |
| CN1297600C (zh) | 2004-07-30 | 2007-01-31 | 胡靖� | 环保防伪型全生物降解塑料发泡及流延成型方法 |
| US7790699B2 (en) * | 2004-10-12 | 2010-09-07 | Fmc Biopolymer As | Self-gelling alginate systems and uses thereof |
| US7700355B2 (en) | 2005-01-07 | 2010-04-20 | Industrial Technology Research Institute | Methods of producing a porous matrix for culturing and recovering cells |
| JP2007068879A (ja) * | 2005-09-09 | 2007-03-22 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
| JP2007143833A (ja) * | 2005-11-28 | 2007-06-14 | National Cardiovascular Center | 生体埋込部材及び人工組織 |
| PT2347775T (pt) * | 2005-12-13 | 2020-07-14 | The President And Fellows Of Harvard College | Estruturas em andaime para transplante celular |
| US20070249044A1 (en) * | 2006-01-30 | 2007-10-25 | University Of Illinois At Chicago | Microstructures in three dimensional gel suspensions for growth of cells |
| CN100415304C (zh) | 2006-03-13 | 2008-09-03 | 西北大学 | 一种可生物降解止血海绵材料及其制备方法 |
| US20070240080A1 (en) * | 2006-04-11 | 2007-10-11 | Invensys Systems, Inc. | Strategy editor for process control supporting drag and drop connections to declarations |
-
2007
- 2007-03-01 CA CA2643084A patent/CA2643084C/en not_active Expired - Fee Related
- 2007-03-01 EP EP20070752153 patent/EP1988937A2/en not_active Withdrawn
- 2007-03-01 US US11/712,611 patent/US20070254016A1/en not_active Abandoned
- 2007-03-01 AT AT07752154T patent/ATE517645T1/de not_active IP Right Cessation
- 2007-03-01 JP JP2008557415A patent/JP2009528437A/ja active Pending
- 2007-03-01 JP JP2008557416A patent/JP2009529926A/ja not_active Ceased
- 2007-03-01 US US11/712,612 patent/US9028872B2/en not_active Expired - Fee Related
- 2007-03-01 EP EP20070752154 patent/EP1988942B1/en not_active Not-in-force
- 2007-03-01 WO PCT/US2007/005436 patent/WO2007103209A2/en not_active Ceased
- 2007-03-01 AU AU2007224138A patent/AU2007224138B2/en not_active Ceased
- 2007-03-01 WO PCT/US2007/005435 patent/WO2007103208A2/en not_active Ceased
- 2007-03-01 BR BRPI0708422-6A patent/BRPI0708422A2/pt not_active IP Right Cessation
- 2007-03-01 AU AU2007224137A patent/AU2007224137A1/en not_active Abandoned
- 2007-03-01 CA CA 2643083 patent/CA2643083A1/en not_active Abandoned
- 2007-03-01 BR BRPI0708429-3A patent/BRPI0708429A2/pt not_active IP Right Cessation
-
2008
- 2008-08-21 IL IL193640A patent/IL193640A/en not_active IP Right Cessation
- 2008-08-21 IL IL193621A patent/IL193621A/en not_active IP Right Cessation
- 2008-08-27 NO NO20083696A patent/NO20083696L/no not_active Application Discontinuation
- 2008-08-29 NO NO20083729A patent/NO20083729L/no not_active Application Discontinuation
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05214156A (ja) * | 1991-10-15 | 1993-08-24 | Merck & Co Inc | ゲル化発泡体 |
| JPH06510330A (ja) * | 1992-06-19 | 1994-11-17 | アルバニー インターナショナル コーポレイション | 多糖フォームの製造方法 |
| JPH08337674A (ja) * | 1995-06-07 | 1996-12-24 | Albany Internatl Res Co | 多糖フォームの製造方法 |
| JP2001278984A (ja) * | 2000-01-24 | 2001-10-10 | Kuraray Co Ltd | 水膨潤性高分子ゲルおよびその製造法 |
| JP2002105233A (ja) * | 2000-09-29 | 2002-04-10 | Kuraray Co Ltd | 多糖類スポンジの製造法及び多糖類スポンジ |
| US20040071776A1 (en) * | 2000-11-22 | 2004-04-15 | Vincent Boudy | Porous plymeric biomaterials, preparation method and uses |
| WO2005023323A1 (en) * | 2003-09-08 | 2005-03-17 | Fmc Biopolymer As | Gelled biopolymer based foam |
| JP2007505183A (ja) * | 2003-09-08 | 2007-03-08 | エフエムシー バイオポリマー エイエス | ゲル化バイオ重合体基材発泡体 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013503656A (ja) * | 2009-09-01 | 2013-02-04 | メドヴェント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 組織ドレッシングキット |
| US9814800B2 (en) | 2009-09-01 | 2017-11-14 | Medovent Gmbh | Tissue dressing kit |
| JP2013529464A (ja) * | 2010-06-22 | 2013-07-22 | ウニヴェルシテ ド ルアン | ３ｄ細胞培養に用いる改良された架橋ヒアルロナンヒドロゲル |
| JP2014514330A (ja) * | 2011-04-29 | 2014-06-19 | ケーシーアイ ライセンシング インク | 創傷環境における治療因子の結合のためのアプタマー変性高分子材料 |
| JP2015527478A (ja) * | 2012-09-07 | 2015-09-17 | スリーエム イノベイティブ プロパティズ カンパニー | シリコーン組成物及び関連方法 |
| JP2017032498A (ja) * | 2015-08-05 | 2017-02-09 | 株式会社武蔵野化学研究所 | エンドトキシンの測定用試料の前処理方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0708422A2 (pt) | 2011-05-31 |
| NO20083729L (no) | 2008-11-12 |
| NO20083696L (no) | 2008-11-12 |
| AU2007224138B2 (en) | 2012-07-19 |
| IL193640A0 (en) | 2009-05-04 |
| ATE517645T1 (de) | 2011-08-15 |
| EP1988942B1 (en) | 2011-07-27 |
| CA2643083A1 (en) | 2007-09-13 |
| AU2007224137A1 (en) | 2007-09-13 |
| IL193621A0 (en) | 2009-05-04 |
| IL193621A (en) | 2013-08-29 |
| CA2643084C (en) | 2015-12-29 |
| WO2007103209A3 (en) | 2008-12-24 |
| JP2009529926A (ja) | 2009-08-27 |
| CA2643084A1 (en) | 2007-09-13 |
| US20080033392A1 (en) | 2008-02-07 |
| WO2007103208A3 (en) | 2008-12-24 |
| EP1988937A2 (en) | 2008-11-12 |
| US9028872B2 (en) | 2015-05-12 |
| US20070254016A1 (en) | 2007-11-01 |
| IL193640A (en) | 2012-12-31 |
| AU2007224138A1 (en) | 2007-09-13 |
| WO2007103209A2 (en) | 2007-09-13 |
| WO2007103208A2 (en) | 2007-09-13 |
| BRPI0708429A2 (pt) | 2011-05-31 |
| EP1988942A2 (en) | 2008-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528437A (ja) | 生分解性発泡体 | |
| JP5328780B2 (ja) | アルギネート被覆多糖ゲル含有発泡体複合物、その製法および用途 | |
| JP6042815B2 (ja) | 生物医学的応用のためのアルギン酸塩及びヒアルロン酸を用いる抗癒着性バリア膜 | |
| US10709817B2 (en) | Biocompatible and bioabsorbable derivatized chitosan compositions | |
| US11168183B2 (en) | Method for the production of hydrogel comprising chitosan and negatively charged polyelectrolytes, and cellular, porous material resulting from said hydrogel | |
| Khor et al. | Implantable applications of chitin and chitosan | |
| Onofrei et al. | Cellulose-based hydrogels: designing concepts, properties, and perspectives for biomedical and environmental applications | |
| JP2009529926A5 (https=) | ||
| JP2009528437A5 (https=) | ||
| CN107397980A (zh) | 一种组织修复膜涂覆用防粘连组合物及其使用方法 | |
| JP4044291B2 (ja) | 水膨潤性高分子ゲルおよびその製造法 | |
| JP2014528406A (ja) | 治療薬を送達するための多層インプラント | |
| Torun et al. | Cellulose Derivatives: Chemical Modification and Biomedical Research Applications | |
| Mohanraj | Plant-derived resorbable polymers in tissue engineering | |
| Mishra et al. | Applications of biodegradable polymeric biomaterials in biomedical science | |
| Magagula et al. | GG Lenetha Department of Life Sciences, Central University of Technology, Private Bag X1, Bloemfontein, South Africa | |
| Yuan et al. | Mechanical design of adhesive hydrogels and their applications in soft tissue regeneration | |
| Cui et al. | Chitosan: a versatile biomedical polymer | |
| ES2368516T3 (es) | Material compuesto gelificado. | |
| JP2000230002A (ja) | 骨修復材 | |
| TW201622759A (zh) | 纖維海綿敷材及其製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100219 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120216 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120523 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121113 |